There’s a brand new beast on the streets — and it’s nothing to bark at.
A strong animal tranquilizer is more and more saturating the US drug provide, fueling mass overdose outbreaks in hotspots like Chicago and Philadelphia.
It was detected in New York final yr, setting off alarm bells amongst public well being officers. They warn that whereas its results can mimic opioids akin to fentanyl, there’s a harmful catch: It doesn’t reply to standard overdose-reversal therapies.
The drug, medetomidine, is a sedative utilized by veterinarians to calm down muscular tissues and relieve ache, typically throughout surgical procedure. It really works by slowing the discharge of adrenaline within the mind and physique.
It’s just like xylazine, or tranq — a veterinary painkiller and muscle relaxant generally minimize into road medicine since about 2020 — but it surely’s much more harmful. Specialists say it may be as much as 20 instances stronger, that means small quantities might be extremely addictive.
Including to the risk, medetomidine is affordable and straightforward to acquire, available on-line by suppliers of veterinary medicines and analysis chemical substances.
Cartels and street-level sellers “are mixing these deadly synthetics into their drug provide … to extend habit, to extend their buyer base, to earn more money,” Frank A. Tarentino III, particular agent accountable for the Drug Enforcement Company’s New York Division, advised The Submit final yr.
“Then you definitely introduce a extra highly effective fentanyl like carfentanil, or medetomidine, which is extra highly effective and extra harmful than xylazine, then you definitely’re speaking about even higher catastrophic overdoses and poisonings than we’re already seeing.”
Medetomidine was first detected within the US illicit drug provide in 2021. By July 2024, it had been present in drug samples and biospecimens of individuals utilizing illicit opioids in at the very least 18 states and Washington, DC.
Since then, consultants say the drug’s footprint has virtually definitely expanded — and so has its physique rely.
When individuals use medetomidine, it slows their coronary heart price and causes heavy sedation that may final for hours and even result in coma. Customers typically expertise negative effects akin to dizziness, excessive fatigue, shortness of breath, nausea, blurred imaginative and prescient and confusion.
However the true nightmare begins when the drug wears off.
Withdrawal might be so extreme that many sufferers require intensive care. Life-threatening signs embody dangerously excessive spikes in coronary heart price and blood strain — excessive sufficient to trigger mind harm — together with uncontrollable vomiting, tremors and profuse sweating.
“Our ICUs have been overwhelmed,” Dr. Daniel del Portal, an emergency room doctor and hospital administrator at Temple Well being in Philadelphia, advised The New York Occasions.
Medetomidine is now exhibiting up extra often than xylazine within the metropolis’s drug provide, a surge that del Portal mentioned docs, emergency medical employees and outreach groups have come to name “the withdrawal disaster.”
Within the first 9 months of 2025 alone, Philadelphia hospitals recorded 7,252 emergency division visits for withdrawal, in contrast with 2,787 in all of 2023, based on metropolis public well being data.
Withdrawals aren’t the one concern.
When individuals overdose on medetomidine, they typically don’t reply to opioid-reversal medicine like naloxone — generally generally known as Narcan — the way in which fentanyl customers do, making overdoses far more durable to reverse.
In instances the place sufferers overdose on a mixture of opioids and medetomidine, naloxone may help restart respiration however doesn’t counteract the sedative results of medetomidine. Consequently, sufferers could stay unconscious.
“From our medical expertise, after sufferers begin to breathe usually, offering extra doses of naloxone doesn’t appear to assist and even dangers prompting opioid withdrawal signs,” Dr. Kory London, an affiliate professor of emergency medication at Thomas Jefferson College, and Dr. Karen Alexander, an adjunct professor on the faculty’s School of Nursing, wrote in The Dialog.
“Naloxone remains to be advisable for an individual exhibiting indicators of opioid overdose — akin to extra sedation, shallow or absent respiration and small pupils,” they added. “But when the affected person begins respiration however doesn’t instantly get up, extra doses of naloxone must be prevented.”
If a suspected overdose sufferer doesn’t reply to naloxone due to medetomidine, well being officers advocate “rescue respiration,” or mouth-to-mouth resuscitation, whereas ready for emergency responders to reach.
